IL2 and renal cell carcinoma: In 2011, Aitchison et al. published findings from the EORTC/NCRI trial, which examined the effects of adjuvant treatments, specifically IL-2, IFN-α, and 5-fluorouracil, on patients at an elevated risk of relapse after undergoing the surgical removal of RCC.